Evidence map›Paper›PMID 37107645›Full record

ArticleGenes2023

Identification of Compound Heterozygous

Nancy Negrete-Torres, María Del Carmen Chima-Galán, Ernesto Antonio Sierra-López, Janet Sánchez-Ramos, Isela Álvarez-González, Julia Reyes-Reali, María Isabel Mendoza-Ramos, Efraín Garrido-Guerrero, Dante Amato, Claudia Fabiola Méndez-Catalá and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Nancy Negrete-TorresLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico.
María Del Carmen Chima-GalánCentro Médico Nacional "20 de Noviembre", ISSSTE, Ciudad de México 03229, Mexico.
Ernesto Antonio Sierra-LópezCentro Médico Nacional "20 de Noviembre", ISSSTE, Ciudad de México 03229, Mexico.
Janet Sánchez-RamosLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico.
Isela Álvarez-GonzálezLaboratorio de Genética, Escuela Nacional de Ciencias Biológicas Zacatenco, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico.ORCID 0000-0003-4011-9121
Julia Reyes-RealiLaboratorio de Inmunología, Unidad de Morfofisiología y Función, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico.
María Isabel Mendoza-RamosLaboratorio de Inmunología, Unidad de Morfofisiología y Función, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico.
Efraín Garrido-GuerreroDepartamento de Genética y Biología Molecular, CINVESTAV-IPN, Ciudad de México 07360, Mexico.
Dante AmatoLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico.
Claudia Fabiola Méndez-CataláLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico.ORCID 0000-0003-3444-1085
Glustein Pozo-MolinaLaboratorio de Genética y Oncología Molecular, Laboratorio 5, Edificio A4, Carrera de Médico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico.ORCID 0000-0002-4675-4081
Adolfo René Méndez-CruzLaboratorio de Inmunología, Unidad de Morfofisiología y Función, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Mexico.
Autonomous University of Tlaxcala · MXInstitute for Social Security and Services for State Workers · MXCentro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXInstituto Politécnico Nacional · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEllis-van Creveld syndrome (EvCS) is an autosomal recessive ciliopathy with a disproportionate short stature, polydactyly, dystrophic nails, oral defects, and cardiac anomalies. It is caused by pathogenic variants in the

methodsTwo Mexican families were enrolled in this study. Exome sequencing was applied in the probands to screen potential genetic variant(s), and then Sanger sequencing was used to identify the variant in the parents. Finally, a prediction of the three-dimensional structure of the mutant proteins was made.

resultsOne patient has a compound heterozygous

conclusionThe identified novel heterozygous

Indexed as

Ellis-Van Creveld SyndromeMembrane ProteinsCodon, NonsenseFemaleHumansIntercellular Signaling Peptides and ProteinsMutationPedigreeCodon, NonsenseIntercellular Signaling Peptides and ProteinsMembrane ProteinsciliopathiesEllis–van Creveld syndromeEVC2 geneMexican patientswhole exome sequencing

Identifiers

PMID37107645
PMCPMC10137610
OpenAlexW4362733549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.